Biologics CDMO Global Market Report 2024

The biologics CDMO market size has grown rapidly in recent years. It will grow from $18.44 billion in 2023 to $21.3 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. The expansion observed during the historical period can be attributed to several factors, including the increased focus on biologics development, cost efficiency, and flexibility offered by CDMOs, pharmaceutical companies' concentration on core competencies, adherence to regulatory compliance and quality assurance standards, as well as the globalization of pharmaceutical supply chains.

The biologics CDMO market size is expected to see rapid growth in the next few years. It will grow to $36.54 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. Anticipated growth in the forecast period can be attributed to several factors, including the increasing demand for biologic therapies, the emergence of biosimilars and bio betters, investments in biomanufacturing infrastructure, a shift towards outsourcing complex processes, a heightened focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Major trends expected during this period encompass the expansion of capabilities to offer end-to-end solutions, adoption of single-use technologies, integration of continuous manufacturing processes, and the emergence of specialized CDMOs.

The escalating demand for cell and genetic therapy is poised to drive the expansion of the biologic Contract Development and Manufacturing Organization (CDMO) market in the foreseeable future. Cell and gene therapy represent cutting-edge medical modalities that harness living cells or genetic material to target underlying disease mechanisms at the cellular or genetic level, offering potential treatments for conditions that are challenging to manage or incurable using conventional pharmaceuticals. The increasing demand for cell and gene therapy stems from their potential to deliver innovative treatments for diseases by addressing fundamental genetic or cellular causes. Biologic CDMOs specialize in handling living cells, viral vectors, and genetic material, facilitating the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical hurdles, thereby facilitating the translation of therapies from research to clinical application. For example, as reported by The American Society of Gene & Cell Therapy (ASGCT), a US-based professional organization, in January 2023, the gene, cell, and RNA therapy pipeline experienced a 7% growth in 2022, totaling 3,726 therapies in development. Of these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Consequently, the upsurge in demand for cell and genetic therapy is propelling the growth of the biologic CDMO market.

Leading companies in the biologic CDMO market are leveraging technological advancements to develop innovative solutions, such as new cell lines, aimed at enhancing biopharmaceutical development and manufacturing efficiency and capabilities. These technologies enable the production of therapeutic antibodies with heightened potency, addressing challenges encountered in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, introduced GS Effex cell lines. These cell lines are engineered to produce antibodies that are 100% devoid of fucose, a sugar molecule, thereby demonstrating increased potency without compromising other performance attributes. GS Effex cell lines offer a solution to challenges in immunotherapy research and development by enhancing the potency of antibody therapeutics. They are characterized by stability, scalability, and productivity, providing a comprehensive solution for therapeutic development from the discovery stage through commercial manufacturing.

In May 2022, Bora Pharmaceuticals Co. Ltd., a Taiwan-based pharmaceutical organization renowned for its manufacturing and distribution of pharmaceutical products, completed the acquisition of the contract development and manufacturing organization (CDMO) assets of Eden Biologics Inc. for a total of $100 million. This strategic move aims to bolster Bora Pharmaceuticals' footprint in the global CDMO market, with a particular focus on expanding its capabilities in biologics, macromolecules, and cell and gene therapy sectors. Eden Biologics Inc., also based in Taiwan, specializes in providing contract development and manufacturing services for innovative biologics intended for therapeutic applications.

Major companies operating in the biologics cdmo market report are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

North America was the largest region in the biologics CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A biologics contract development and manufacturing organization (CDMO) is a service provider that aids pharmaceutical companies in the development and manufacturing of biologic drugs. These drugs encompass a wide range of products such as vaccines, blood components, allergens, gene therapies, tissues, and recombinant therapeutic proteins.

The primary cell types utilized in biologics CDMOs are mammalian and non-mammalian cells. Mammalian cells are derived from mammals and are commonly employed in the production of biologics and cell-based therapies due to their capability to produce complex proteins and maintain post-translational modifications. The products offered typically include biologics and biosimilars.

The biologics CDMO research report is one of a series of new reports that provides biologics CDMO market statistics, including the biologics CDMO industry's global market size, regional shares, competitors with an biologics CDMO market share, detailed biologics CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the biologics CDMO industry. This biologics CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.